NKX6-3

Across TCGA pan-cancer cohorts, NKX6-3 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated NKX6-3 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher NKX6-3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NKX6-3 expression acts as an unfavorable survival marker.

DLBC are the cancer types where NKX6-3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

NKX6-3–DLBC (OS)

Open the DLBC breakdown →